<DOC>
	<DOCNO>NCT01265914</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability immunogenicity ascend dos novel , universal flu vaccine , healthy volunteer .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Immunogenicity Universal Influenza A Vaccine</brief_title>
	<detailed_description>FP-01.1 compose mixture synthetic peptide , modify fluorocarbon vector , anticipate enhance immune property drug , allow differentiation recent investigational intervention avoid use adjuvant . The peptide sequence , derive internal influenza-A protein , select base presence CD4+ CD8+ T cell epitopes high degree conservation across influenza strain , use proprietary bioinformatics approach , , propose , enable FP-01.1 universally treat influenza-A -infected population . This study initial exploration safety , tolerability immunogenicity response FP-01.1 healthy volunteer . Ascending dose FP-01.1 assess .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>1 . Age 18 55 year inclusive time consent 2 . Male female subject willing comply applicable contraceptive requirement protocol 3 . Satisfactory medical assessment clinically significant relevant abnormality medical history , physical examination , vital sign , ECG laboratory evaluation ( haematology , biochemistry urinalysis ) assess Investigator . 4 . Ability provide write , personally sign date informed consent participate study . 5 . The subject body mass index within range 19.032.0 kg/m2 fall within weight range 50.0100.0 kg . 6 . Subject willing refrain consume alcohol 24h prior visit . 1 . As result medical screening process , Principal Investigator CoInvestigator considers subject unfit study . 2 . Current recurrent disease ( e.g . cardiovascular , respiratory , endocrine , renal , liver , gastrointestinal , autoimmune , immune suppression , malignancy condition ) could affect action , absorption disposition investigational medicinal product ( IMP ) could affect clinical laboratory assessment . 3 . Significant illness judge Principal Investigator CoInvestigator within 2 week first dose IMP . 4 . Subjects history allergy allergic condition include asthmatic , hay fever eczema sufferer require medication opinion Principal Investigator CoInvestigator affect participation study . 5 . Concurrent use medication ( include prescription , counter , herbal homeopathic preparation vaccination ( include travel vaccination ) . 6 . Known suspected intolerance hypersensitivity IMP/placebo , closely related compound state ingredient . 7 . History alcohol substance abuse within last year . A positive screen alcohol drug abuse . 8 . Male subject consume 21 unit alcohol per week female subject consume 14 unit alcohol per week . 9 . A positive HIV antibody screen , Hepatitis B surface antigen , Hepatitis B core antibody , Hepatitis C antibody screen 10 . Subjects significant scarring , tattoo , abrasion , cut infection dose site opinion Investigator could interfere evaluation injection site local reaction . 11 . Donation blood blood product ( e.g . plasma , platelet ) within 90 day prior intention donate blood entire study . 12 . Use another investigational medicinal product within 90 day prior receive first dose IMP intention enrol another clinical study throughout entire study include follow period . 13 . Subject suspect recent ( â‰¤12 month ) preexposure influenza A virus 14 . Subjects receive flu vaccine last 12 month anticipate receive within duration study include follow . 15 . Any clinically significant abnormality , opinion Principal Investigator CoInvestigator , electrocardiogram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>